Invitation to presentation of Xbrane Biopharma’s interim report January – September 2020 on November 13, 2020.

Corporate Information

English

News

Other Corporate Information

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on November 13, 2020, at 10.00 a.m. CET. Xbrane will publish the company’s interim report January – September 2020, on Friday November 13, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Margareta Hagman, Interim CFO, will present Xbrane and the interim report January – September 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below or click on the link below to follow the presentation.

Standard international: +44 (0) 2071 928338
UK (Local): +44 (0) 8444819752
UK (Tollfree): 08002796619
Sweden (Local): +46 (0) 856618467
Sweden (TollFree): 0200125160
US (LocaL): +1 6467413167
US (TollFreee): +1 8778709135

Confirmation Code: 1225339

Web link:

https://edge.media-server.com/mmc/p/jcuq48x6

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.